



Cite this: *Chem. Commun.*, 2015, 51, 3608

Received 14th November 2014,
Accepted 12th January 2015

DOI: 10.1039/c4cc09107h

www.rsc.org/chemcomm

Facile synthesis of borofragments and their evaluation in activity-based protein profiling†

Shinya Adachi,^a Armand B. Cognetta 3rd,^b Micah J. Niphakis,^b Zhi He,^a Adam Zajdlik,^a Jeffrey D. St. Denis,^a Conor C. G. Scully,^a Benjamin F. Cravatt^b and Andrei K. Yudin^{*a}

The discovery of enzyme inhibitors relies on synthetic methods that enable rapid and modular construction of small molecules. Heterocyclic fragments designed to maximize enthalpic interactions with their protein targets represent a particularly desirable class of molecules. Here we describe a reagent that enables straightforward construction of “borofragments”, in which a heterocycle is separated from the boron center by two or three rotatable bonds. The stability of these molecules depends on the MIDA group which likely acts as a slow-release element under biological conditions. Borofragments can be used to discover inhibitors of enzymes that use catalytic oxygen nucleophiles. We have employed this method to identify inhibitors of ABHD10 and the predicted carboxypeptidase CPVL. This technique should be applicable to other classes of targets.

Organoboron compounds have received considerable attention as valuable building blocks in chemical synthesis.¹ Boron-containing molecules have also been used as enzyme inhibitors.² Both of these applications result from the accessibility of boron's empty p-orbital, which enables reversible interaction with synthetic and biological nucleophiles. Our recent interest in this area has led to an ongoing exploration of boron-based electrophiles that engage nucleophilic residues in active sites of proteins. In contrast to aldehydes, acrylates and epoxides, which are widely used as “baits” for nucleophilic residues in active sites, small boron-containing electrophiles have received relatively little attention. This is mainly due to their lack of stability and relative difficulty of preparation, especially when it comes to molecules with C(sp³)-B bonds.¹ Because the corresponding synthetic protocols often depend on organometallic

reactions with low functional group tolerance, we recently developed a boron-containing isocyanide reagent that enabled us to synthesize novel boromorpholinones and boropeptides under mild conditions.³ The *N*-methyliminodiacetic acid (MIDA) residue on boron^{4,5} was the main factor that contributed to the stability of boropeptides and their successful one-step synthesis.

Building on our approach to boropeptides, we became interested in advancing the concept of MIDA-containing borofragments, which are chimeric molecules where a boron-containing group is connected to a recognition unit, most commonly a heterocycle. As many biologically relevant heterocycles with high ligand efficiency have conjugate acids with relatively low pK_a's,⁶ we were motivated to develop a mild method for connecting a diverse set of heterocyclic nucleophiles to the smallest possible C-B unit equipped with the MIDA substituent (furnishing the corresponding borofragments). To facilitate navigation of the accessible chemistry space in enzyme active sites, we were particularly intrigued by the borofragments in which a heterocycle is separated from the boron center by two or three rotatable bonds. In this paper, we present our efforts to synthesize electrophilic borofragments and their evaluation as serine hydrolase inhibitors using competitive activity-based protein profiling (ABPP). We show that the MIDA group is compatible with the synthesis of a diverse collection of borofragments and that select members of this class inhibit several poorly characterized serine hydrolases, including α/β hydrolase domain-containing protein 10 (ABHD10) and predicted serine carboxypeptidase (CPVL). These findings should encourage broader campaigns to append C(sp³)-B bonds in their MIDA forms to various molecular recognition components.


In order to convert readily accessible nucleophilic small molecules into borofragments, we pursued hydroxymethyl-containing building block **5** with the goal of evaluating its reactivity in redox-driven condensations. Despite the relative bulk of the MIDA group, the mild and neutral conditions⁷ of the Mitsunobu process were particularly attractive to us. Compound **5** was synthesized according to Scheme 1. Starting with dibromomethane (**1**), bromomethylpinacolborate (**2**) was

^a Davenport Research Laboratories, Department of Chemistry, University of Toronto, 80 St. George St., Toronto, ON M5S3H6, Canada.

E-mail: ayudin@chem.utoronto.ca

^b The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

† Electronic supplementary information (ESI) available. CCDC 1021097–1021099. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c4cc09107h
























Scheme 1 Preparation of hydroxymethyl(MIDA)boronate.

prepared according to literature procedure.⁸ Treatment of **1** with *n*-butyllithium in the presence of triisopropoxyborate followed by transesterification of the resulting bromomethyl-diisopropoxyborane with pinacol furnished intermediate **2**. Subsequent treatment of crude product **2** with sodium benzyl-oxide in DMSO afforded benzyloxymethylpinacolboronic ester (**3**),⁹ which was converted to benzyloxymethyl(MIDA)boronate (**4**) *in situ* by heating in the presence of MIDA. Most importantly, purification of compound **4** was achieved by trituration with Et₂O, which eliminated the need for chromatography. Hydrogenolysis of **4** with Pd/C afforded hydroxymethyl(MIDA)-boronate (**5**) as a bench-stable white solid in pure form (49% isolated yield over 4 steps, > 10 g).

We were pleased to observe that, despite the steric bulk of the *B*-MIDA substituent, hydroxymethyl(MIDA)boronate (**5**) reacted with various acidic pro-nucleophiles (NuH) in the presence of diisopropyl azodicarboxylate (DIAD) and triphenylphosphine to produce a variety of α -functionalized alkyl(MIDA)-boronates in excellent yields (Table 1). Ester formation *via* coupling of benzoic acid (**6a**) or cinnamic acid (**6b**) with **5** afforded the corresponding products **7a** and **7b**, respectively (entries 1 and 2). *N*-Hydroxyphthalimide (**6c**) was easily converted into the corresponding heterocyclic product **7c** (entry 3). Etherification of **5** was also carried out. Thus, phenol **6d** was used to produce **7d**, although 2.0 equivalents of **6d** were required in this case (entry 4). Nitrogen-containing acidic pro-nucleophiles were also employed in this methodology (entries 5 and 6). The reaction of phthalimide (**6e**) with **5** gave the corresponding product **7e** (entry 5). *N,O*-Bis(phenoxycarbonyl)hydroxylamine (**6f**)¹⁰ was converted to **7f** (entry 6). Purine derivatives **6g** and **6h**¹¹ were found to react with **5** to afford *N*(9)-alkylated products **7g** and **7h**, whose structures were confirmed by X-ray crystallography (entries 7 and 8). Sulfur-containing pro-nucleophiles **6i,j** reacted with **5** to afford the corresponding products **7i,j** (entries 9 and 10). For compounds **7a–e,g,j** purification was achieved by trituration with Et₂O due to the low solubility of the products in non-polar solvents. We note that Molander and co-workers have reported the nucleophilic substitution of α -halomethyltrifluoroborates with nucleophiles such as amines and organolithium/organosodium reagents.¹² Their work also includes nucleophilic substitutions of α -halomethylboronic esters with amines followed by addition of KHF₂ to synthesize a number of α -functionalized alkyl trifluoroborates.¹³ However, those substitutions have been conducted under basic conditions and often at high temperatures. In contrast, our reactions are carried out at

Table 1 Synthesis of α -functionalized alkyl(MIDA)boronates^a


				
Entry	NuH	Product		Yield (%)
1 ^b	6a 	7a		99
2 ^b	6b 	7b		94
3	6c 	7c		97
4 ^c	6d 	7d		91
5	6e 	7e		99
6	6f 	7f		78
7	6g 	7g		98
8	6h 	7h		96
9	6i 	7i		85
10	6j 	7j		92

^a Unless otherwise noted, reactions were conducted with alcohol (1.0 equiv.), 1.0 equiv. of acidic pronucleophile, 1.2 equiv. of triphenylphosphine, and 1.2 equiv. of DIAD in THF at 23 °C for 30 min. ^b 1.5 equiv. of acidic pronucleophile, 1.5 equiv. of triphenylphosphine, and 1.5 equiv. of DIAD were used. Reaction time: 30 min. Temp.: 23 °C. ^c 2.0 equiv. of acidic pronucleophile, 1.5 equiv. of triphenylphosphine, and 1.5 equiv. of DIAD were used. Reaction time: 12 h. Temp.: 23 °C.

neutral pH and room temperature, thus expanding the scope of compatible functional groups, which includes biologically relevant heterocycles with low pK_a's.

We were also able to incorporate the azide function *via* a modified Mitsunobu reaction of hydroxymethyl(MIDA)boronate (**5**) with diphenylphosphoryl azide (DPPA) (**8**). This reaction produced azidomethyl(MIDA)boronate (**9**) in 90% yield (Scheme 2).¹⁴ Compound **9** was also synthesized through an alternate route in 75% yield from the reaction of sodium azide with iodomethyl-(MIDA)boronate (**10**), which was in turn prepared by treatment of **5** with iodine, PPh₃, and imidazole. The presence of an azide in compound **9**, which can be elaborated *via* click chemistry,¹⁵ further expands the synthetic versatility of borofragment construction.

While boronic acids and their derivatives have been explored as enzyme inhibitors for decades,² their potency and selectivity across mechanistically conserved enzyme classes remains poorly



Scheme 2 Synthesis of azidomethyl(MIDA)boronate.

understood. In large part this is due to the poor stability of free boronic acids under biological conditions and the consequential lack of compounds for analysis. We have found that the MIDA ligand enables preparation of compounds unavailable in their free boronic acid form, yet in a biological milieu would likely be released to form active boronic acids. With this in mind, we wondered if broadly profiling the activity of serine hydrolases in the presence of our (MIDA)boronate fragments would elucidate novel inhibitor–enzyme pairs that could aid functional annotation of poorly characterized enzymes within this class. Using competitive activity-based protein profiling (ABPP) with the serine hydrolase-directed activity-based probe fluorophosphonate–rhodamine (FP–Rh),¹⁶ we first assayed 10 library members (Table 1) across the serine hydrolases natively expressed in a human prostate cancer cell line (PC3). Briefly, a soluble PC3 cell proteomic lysate was treated with either DMSO or a (MIDA)boronate (10 μ M) for 30 min at 37 $^{\circ}$ C and then with FP–Rh (1.0 μ M) for 30 min. The enzymes labeled by FP–Rh were then resolved by SDS–PAGE and their degree of labeling was measured by fluorescence gel imaging. This initial screen revealed that, while most of these compounds did not affect FP–labeling for any detectable serine hydrolase, two thioether boronates (**7i** and **7j**) displayed moderate inhibition of a \sim 30 kDa band which we have previously identified¹⁷ as ABHD10 (Fig. S1, ESI[†]). Considering that enzyme inhibition might necessitate decomposition of the (MIDA)boronate fragments to an active boronic acid (Scheme 3), we retested each compound at 20 μ M with an extended 2 h preincubation time prior to adding FP–Rh, allowing more time for the formation of the putative boronic acid (Fig. 1A). Notably, this preincubation time was sufficient to produce $>95\%$ conversion of **7j** to its corresponding boronic acid in DPBS (see ESI[†]). Using this new assay protocol, **7i** and **7j** displayed enhanced activity, completely inhibiting ABHD10 with few observable off-targets. We and others have recently shown that ABHD10, a poorly characterized serine hydrolase, is also potently inhibited by β -lactones^{17,18} and aza- β -lactams,¹⁹ but to our knowledge, targeting this enzyme with boron-based inhibitors has not been reported. To further assess the potency and selectivity of **7j**, we next tested this



Scheme 3 *In situ* hydrolysis of **7j** to the boronic acid **11** and its covalent reaction with the active site nucleophile of ABHD 10.

Fig. 1 Competitive ABPP of (MIDA)boronates in PC3 cell lysates. (A) Gel-based ABPP analysis of (MIDA)boronates in the soluble proteome of PC3 cells. The proteome was treated with either DMSO or compounds **7a–j** (20 μ M) for 2 h, then treated with FP–Rh (1.0 μ M) for 30 min. Labeled serine hydrolases were resolved by SDS–PAGE and analyzed by fluorescence gel imaging. (B) Gel-based ABPP analysis of **7j** (1.0 nM–100 μ M) and DMSO in the soluble fraction of PC3 cells showing dose-dependent inhibition of ABHD10 and ACOT1/2. (C) ABPP–SILAC analysis of **7j** at 25 μ M (heavy) versus DMSO (light) in whole PC3 cell proteomic lysates showing inhibition of ABHD10, CPVL and, to a lesser extent, ACOT1/2. Data are presented as the mean \pm standard deviations of heavy/light ratios for multiple unique peptides from each serine hydrolase.

compound across a broad concentration range using gel-based ABPP (Fig. 1B). From this analysis, we observed near complete inhibition of ABHD10 at 10 μ M and acyl-coenzyme A thioesterase 1/2 (ACOT1/2)²⁰ (acyl-CoA thioesterases which are involved in fatty acid metabolism²¹) at 100 μ M. Although **7j** is less potent for ABHD10 relative to previously described inhibitors,^{17,19a} it should be emphasized that the ABPP platform used herein, which relies on an irreversible FP probe to report target occupancy, may underestimate the degree of enzyme inhibition for reversible inhibitors, such as boronates/boronic acids, unless the kinetics of FP probe reactivity is carefully monitored using competitive ABPP experiments. This question can be addressed in future studies using established protocols.^{19b}

To definitively identify the targets of **7j**, we used a quantitative mass spectrometry (MS)-based platform termed ABPP–SILAC.²² Following previously described protocols, cell lysates were prepared from PC3 cells cultured in the presence of isotopically light and heavy lysine and arginine. These lysates were then treated with either DMSO (light) or 25 μ M **7j** (heavy) for 2 h and subsequently treated with a biotinylated FP probe (FP–biotin)²³ for 30 min. After mixing the heavy and light proteomes in equal proportions, the biotinylated proteins were enriched by streptavidin chromatography, trypsinized on bead and analyzed by LC–MS/MS to quantify the extent of inhibition

for the identified serine hydrolases. Among ~30 serine hydrolases only two targets were maximally inhibited (> 95%): ABHD10 and the predicted carboxypeptidase CPVL. While the former target was inferred from the gel profiles, we had not detected CPVL by gel-based profiling. Given that CPVL remains poorly annotated with regard to its endogenous substrates and physiological function, there is a clear need for the development of selective inhibitors of this enzyme, which to our knowledge are still lacking. Our data suggest that the (MIDA)boronates described herein are promising leads for CPVL inhibitor development and may facilitate studying the role of this enzyme in human biology.

In summary, the hydroxymethyl(MIDA)boronate reagent disclosed in this paper allows for straightforward conjugation of boron with heterocycles of biological significance. Significantly, the MIDA group stabilizes borofragments against premature decomposition and is likely released under biological conditions to unmask an active boronic acid. This chemistry allowed us to generate new boron-containing inhibitors of ABHD10 and the predicted carboxypeptidase CPVL. Given the diversity of heterocycles that are either commercially available or exist in the historical collections of the pharmaceutical industry, our straightforward method of linking molecular recognition units with stabilized boron electrophiles should enable facile exploration of previously uncharted covalent inhibitor space.

We thank NSERC and NIH (DA033760) for financial support and Dr A. Lough for the X-ray structural analysis of **7f**, **7g**, and **7h**.

Notes and references

- (a) *Science of Synthesis: Boron Compounds*, ed. D. E. Kaufmann and D. S. Matteson, Georg Thieme Verlag, Stuttgart-New York, 2004, vol. 6; (b) *Boronic Acids: Preparation and Applications in Organic Synthesis, Medicine and Materials*, ed. D. G. Hall, Wiley-VCH, Weinheim, 2nd edn, 2011.
- (a) S. J. Baker, J. W. Tomsho and S. J. Benkovic, *Chem. Soc. Rev.*, 2011, **40**, 4279–4285; (b) R. Smoum, A. Rubinstein, V. M. Dembitsky and M. Srebnik, *Chem. Rev.*, 2012, **112**, 4156–4220.
- A. Zajdlik, Z. Wang, J. L. Hickey, A. Aman, A. D. Schimmer and A. K. Yudin, *Angew. Chem., Int. Ed.*, 2013, **52**, 8411–8415.
- (a) E. P. Gillis and M. D. Burke, *J. Am. Chem. Soc.*, 2007, **129**, 6716–6717; (b) S. J. Lee, K. C. Gray, J. S. Paek and M. D. Burke, *J. Am. Chem. Soc.*, 2008, **130**, 466–468; (c) E. P. Gillis and M. D. Burke, *J. Am. Chem. Soc.*, 2008, **130**, 14084–14085; (d) D. M. Knapp, E. P. Gillis and M. D. Burke, *J. Am. Chem. Soc.*, 2009, **131**, 6961–6963; (e) S. G. Ballmer, E. P. Gillis and M. D. Burke, *Org. Synth.*, 2009, **86**, 344–359; (f) E. P. Gillis and M. D. Burke, *Aldrichimica Acta*, 2009, **42**, 17–27; (g) B. E. Uno, E. P. Gillis and M. D. Burke, *Tetrahedron*, 2009, **65**, 3130–3138; (h) J. R. Struble, S. J. Lee and M. D. Burke, *Tetrahedron*, 2010, **66**, 4710–4718; (i) G. R. Dick, D. M. Knapp, E. P. Gillis and M. D. Burke, *Org. Lett.*, 2010, **12**, 2314–2317; (j) S. J. Lee, T. M. Anderson and M. D. Burke, *Angew. Chem., Int. Ed.*, 2010, **49**, 8860–8863; (k) E. M. Woerly, A. H. Cherney, E. K. Davis and M. D. Burke, *J. Am. Chem. Soc.*, 2010, **132**, 6941–6943; (l) S. Fujii, S. Y. Chang and M. D. Burke, *Angew. Chem., Int. Ed.*, 2011, **50**, 7862–7864; (m) J. Li and M. D. Burke, *J. Am. Chem. Soc.*, 2011, **133**, 13774–13777; (n) E. M. Woerly, J. R. Struble, N. Palyam, S. P. O'Hara and M. D. Burke, *Tetrahedron*, 2011, **67**, 4333–4343; (o) G. R. Dick, E. M. Woerly and M. D. Burke, *Angew. Chem., Int. Ed.*, 2012, **51**, 2667–2672; (p) E. M. Woerly, J. E. Miller and M. D. Burke, *Tetrahedron*, 2013, **69**, 7732–7740; (q) E. M. Woerly, J. Roy and M. D. Burke, *Nat. Chem.*, 2014, **6**, 484–491.
- (a) Z. He and A. K. Yudin, *J. Am. Chem. Soc.*, 2011, **133**, 13770–13773; (b) Z. He, A. Zajdlik, J. D. St. Denis, N. Assem and A. K. Yudin, *J. Am. Chem. Soc.*, 2012, **134**, 9926–9929; (c) Z. He, P. Trinchera, S. Adachi, J. D. St. Denis and A. K. Yudin, *Angew. Chem., Int. Ed.*, 2012, **51**, 11092–11096; (d) J. D. St. Denis, A. Zajdlik, J. Tan, P. Trinchera, C. F. Lee, Z. He, S. Adachi and A. K. Yudin, *J. Am. Chem. Soc.*, 2014, **136**, 17669–17673.
- (a) D. A. Erlanson, R. S. McDowell and T. O'Brien, *J. Med. Chem.*, 2004, **47**, 3463–3482; (b) P. Bamborough, M. J. Brown, J. A. Christopher, C.-W. Chung and G. W. Mellor, *J. Med. Chem.*, 2011, **54**, 5131–5143; (c) R. M. Miller, V. O. Paavilainen, S. Krishnan, I. M. Serafimova and J. Taunton, *J. Am. Chem. Soc.*, 2013, **135**, 5298–5301.
- (a) O. Mitsunobu, *Synthesis*, 1981, 1–28; (b) K. C. K. Swamy, N. N. B. Kumar, E. Balaraman and K. V. P. P. Kumar, *Chem. Rev.*, 2009, **109**, 2551–2651.
- N. Murai, M. Yonaga and K. Tanaka, *Org. Lett.*, 2012, **14**, 1278–1281.
- R. P. Singh and D. S. Matteson, *J. Org. Chem.*, 2000, **65**, 6650–6653.
- A. O. Stewart and D. W. Brooks, *J. Org. Chem.*, 1992, **57**, 5020–5023.
- S. Dey and P. Garner, *J. Org. Chem.*, 2000, **65**, 7697–7699.
- G. A. Molander and J. Ham, *Org. Lett.*, 2006, **8**, 2031–2034.
- (a) G. A. Molander and M.-A. Hiebel, *Org. Lett.*, 2010, **12**, 4876–4879; (b) G. A. Molander and I. Shin, *Org. Lett.*, 2012, **14**, 4458–4461.
- B. Lal, B. N. Pramanik, M. S. Manhas and A. K. Bose, *Tetrahedron Lett.*, 1977, **18**, 1977–1980.
- H. C. Kolb, M. G. Finn and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2001, **40**, 2004–2021.
- M. P. Patricelli, D. K. Giang, L. M. Stamp and J. J. Burbaum, *Proteomics*, 2001, **1**, 1067–1071.
- N. J. Lajkiewicz, A. B. Coggnetta, III, M. J. Niphakis, B. F. Cravatt and J. A. Porco, *J. Am. Chem. Soc.*, 2014, **136**, 2659–2664.
- A. List, E. Zeiler, N. Gallastegui, M. Rusch, C. Hedberg, S. A. Sieber and M. Groll, *Angew. Chem., Int. Ed.*, 2014, **53**, 571–574.
- (a) A. M. Zuhl, J. T. Mohr, D. A. Bachovchin, S. Niessen, K.-L. Hsu, J. M. Berlin, M. Dochnahl, M. P. López-Alberca, G. C. Fu and B. F. Cravatt, *J. Am. Chem. Soc.*, 2012, **134**, 5068–5071; (b) D. Leung, C. Hardouin, D. L. Boger and B. F. Cravatt, *Nat. Biotechnol.*, 2003, **21**, 687–691.
- We have previously suggested that this band corresponds to either ACOT1, ACOT2 or both (see ref. 17), by correlating gel-based to MS-based ABPP profiling along with the predicted molecular weight and gel migration profile of these enzymes. However, the high sequence identity between these two distinct enzymes has hampered a definitive assignment.
- B. Kirkby, N. Roman, B. Kobe, S. Kellie and J. K. Forwood, *Prog. Lipid Res.*, 2010, **49**, 366–377.
- (a) A. Adibekian, B. R. Martin, C. Wang, K.-L. Hsu, D. A. Bachovchin, S. Niessen, H. Hoover and B. F. Cravatt, *Nat. Chem. Biol.*, 2011, **7**, 469–478; (b) D. A. Bachovchin, J. T. Mohr, A. E. Speers, C. Wang, J. M. Berlin, T. P. Spicer, V. Fernandez-Vega, P. Chase, S. S. Hodder, S. C. Schürer, D. K. Nomura, H. Rosen, G. C. Fu and B. F. Cravatt, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 6811–6816.
- Y. Liu, M. P. Patricelli and B. F. Cravatt, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 14694–14699.